ALK and non-small cell lung carcinoma: This study shows that compared with chemotherapy alone, first-line use of sintilimab combined with chemotherapy for advanced/recurrent non-squamous NSCLC without EGFR+ mutations or ALK gene rearrangement has significant benefits.